Cover Image
Market Research Report

Hemophilia Gene Therapy Market - Size, Share, Trends, and Forecast to 2026

Published by Coherent Market Insights Product code 798075
Published Content info 110 Pages
Delivery time: 2-3 business days
Price
Back to Top
Hemophilia Gene Therapy Market - Size, Share, Trends, and Forecast to 2026
Published: February 7, 2019 Content info: 110 Pages
Description

Hemophilia is a genetic disorder in which patient's blood do not clot normally due to lack of blood-clotting proteins known as coagulating factors. Conventional treatment options include timely replacement of the specific clotting factor. Major pharma and biotech companies are conducting research and development to develop gene therapy for hemophilia due to various shortcomings with conventional therapy. Increasing number of hemophilic patients that require treatment and strong product pipeline are expected to drive growth of the hemophilia gene therapy market.

Market Dynamics

Major factors that are driving growth of the hemophilia gene therapy market include increasing prevalence of hemophilia, issue of high cost, access to current hemophilia treatment, which includes coagulation factor VIII and IX, and increasing number of companies engaged in research and development of gene therapy products. According to the Centers for Disease Control and Prevention, hemophilia A is a rare, X-linked bleeding disorder that affects around 1 in 5,000 to 10,000 live-born males. Hemophilia B is less common than hemophilia A, with an incidence of around 1 in 25,000 births. According to 2016 global survey by the World Federation of Hemophilia, the total number of individuals with hemophilia worldwide was 184,723, including 16,949 within the U.S.

Key features of the study:

  • This report provides in-depth analysis of the global hemophilia gene therapy market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2018 - 2026), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, pipeline analysis, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global hemophilia gene therapy market based on the following parameters - company overview, financial performance, market presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include BioMarin Pharmaceuticals, Inc., Spark Therapeutics, Pfizer, Inc., UniQure NV, Ultragenyx Pharmaceutical, Shire PLC, Sangamo Therapeutics, Inc., and Freeline Therapeutics
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, product up-gradation, market expansion, and marketing tactics
  • The global hemophilia gene therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the hemophilia gene therapy market

Detailed Segmentation

  • Global Hemophilia Gene Therapy Market, By Type:
  • Hemophilia A
  • Hemophilia B
  • Global Hemophilia Gene Therapy Market, By Region:
  • North America
    • By Type
  • Hemophilia A
  • Hemophilia B
    • By Country:
  • U.S.
  • Canada
  • Latin America
    • By Type
  • Hemophilia A
  • Hemophilia B
    • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Type
  • Hemophilia A
  • Hemophilia B
    • By Country:
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Type
  • Hemophilia A
  • Hemophilia B
    • By Country:
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Type
  • Hemophilia A
  • Hemophilia B
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Type
  • Hemophilia A
  • Hemophilia B
    • By Country:
  • South Africa
  • Central Africa
  • North Africa
  • Company Profiles
  • BioMarin Pharmaceuticals, Inc. *
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Market Strategies
  • Spark Therapeutics
  • Pfizer, Inc.
  • UniQure NV
  • Ultragenyx Pharmaceutical
  • Shire PLC
  • Sangamo Therapeutics
  • Freeline Therapeutics

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Hemophilia Type
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Pipeline Analysis
  • Primary Research Respondents View About Market
  • Mergers, Acquisitions, and Collaborations
  • Regulatory Scenario
  • PEST Analysis
  • Epidemiological Data

4. Global Hemophilia Gene Therapy Market, By Product Type, 2018 - 2026, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2017 and 2025 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Hemophilia A
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
  • Hemophilia B
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)

5. Global Hemophilia Gene Therapy Market, By Region, 2018 - 2026, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2017 and 2026 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017 - 2026
  • North America
    • Market Size and Forecast, By Hemophilia Type, 2016 - 2026, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Hemophilia Type, 2016 - 2026, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Hemophilia Type, 2016 - 2026, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Hemophilia Type, 2016 - 2026, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Hemophilia Type, 2016 - 2026, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Hemophilia Type, 2016 - 2026, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

6. Competitive Landscape

  • Market Share Analysis
  • Company Profiles
    • BioMarin Pharmaceuticals, Inc.*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Spark Therapeutics
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • UniQure NV
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Ultragenyx Pharmaceutical
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Shire PLC
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Sangamo Therapeutics, Inc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Freeline Therapeutics
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
  • Analyst Views

7. Section

  • References
  • Research Methodology
  • About us and Sales Contact
Back to Top